Natural History of Type 1 Interferonopathies: Insights From a European Cohort
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 500
- 试验地点
- 47
- 主要终点
- Characterizing disease progression in pediatric and adult patients with type I interferonopathies
研究概览
简要总结
Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.
Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.
In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.
The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.
The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Genetically confirmed patient with type I interferonopathy
- •Patient affiliated to a social security scheme or beneficiary of such a scheme.
排除标准
- •- Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.
研究组 & 干预措施
Patients
Patients with genetically confirmed type I interferonopathy
结局指标
主要结局
Characterizing disease progression in pediatric and adult patients with type I interferonopathies
时间窗: 2025-2045
Composite description of phenotypes of patients with type I interferonopathies according to genotype (clinical, biological) over time.
次要结局
- Identifing and characterising genotype-specific immunological factors(2025-2045)
- Research of biomarkers for diagnosis, prognosis and monitoring of disease activity(2025-2045)
- Monitoring of treatment response according to phenotype and genotype(2025-2045)
